VXRT vs. ATHA, ALGS, INO, EXAI, KYTX, ADPT, CABA, LXEO, ALEC, and TCRX
Should you be buying Vaxart stock or one of its competitors? The main competitors of Vaxart include Athira Pharma (ATHA), Aligos Therapeutics (ALGS), Inovio Pharmaceuticals (INO), Exscientia (EXAI), Kyverna Therapeutics (KYTX), Adaptive Biotechnologies (ADPT), Cabaletta Bio (CABA), Lexeo Therapeutics (LXEO), Alector (ALEC), and TScan Therapeutics (TCRX). These companies are all part of the "medical" sector.
Vaxart (NASDAQ:VXRT) and Athira Pharma (NASDAQ:ATHA) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, dividends, institutional ownership, earnings, community ranking, valuation, risk, media sentiment and analyst recommendations.
Vaxart currently has a consensus target price of $3.00, indicating a potential upside of 268.10%. Athira Pharma has a consensus target price of $19.00, indicating a potential upside of 625.19%. Given Athira Pharma's higher probable upside, analysts plainly believe Athira Pharma is more favorable than Vaxart.
Vaxart has higher revenue and earnings than Athira Pharma. Vaxart is trading at a lower price-to-earnings ratio than Athira Pharma, indicating that it is currently the more affordable of the two stocks.
In the previous week, Athira Pharma had 3 more articles in the media than Vaxart. MarketBeat recorded 4 mentions for Athira Pharma and 1 mentions for Vaxart. Vaxart's average media sentiment score of 1.89 beat Athira Pharma's score of 1.55 indicating that Vaxart is being referred to more favorably in the media.
18.1% of Vaxart shares are owned by institutional investors. Comparatively, 57.1% of Athira Pharma shares are owned by institutional investors. 3.0% of Vaxart shares are owned by insiders. Comparatively, 19.8% of Athira Pharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Vaxart received 291 more outperform votes than Athira Pharma when rated by MarketBeat users. Likewise, 65.47% of users gave Vaxart an outperform vote while only 58.06% of users gave Athira Pharma an outperform vote.
Vaxart has a beta of 0.72, meaning that its share price is 28% less volatile than the S&P 500. Comparatively, Athira Pharma has a beta of 2.83, meaning that its share price is 183% more volatile than the S&P 500.
Athira Pharma has a net margin of 0.00% compared to Vaxart's net margin of -920.00%. Athira Pharma's return on equity of -80.59% beat Vaxart's return on equity.
Summary
Athira Pharma beats Vaxart on 9 of the 16 factors compared between the two stocks.
Get Vaxart News Delivered to You Automatically
Sign up to receive the latest news and ratings for VXRT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding VXRT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
